| A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics EJ Cox, N Maharao, G Patilea-Vrana, JD Unadkat, AE Rettie, JS McCune, ... Pharmacology & therapeutics 201, 25-38, 2019 | 88 | 2019 |
| Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450 S Bansal, N Maharao, MF Paine, JD Unadkat Drug Metabolism and Disposition 48 (10), 1008-1017, 2020 | 61 | 2020 |
| Entering the era of computationally driven drug development N Maharao, V Antontsev, M Wright, J Varshney Drug Metabolism Reviews 52 (2), 283-298, 2020 | 35 | 2020 |
| Accelerated repurposing and drug development of pulmonary hypertension therapies for COVID-19 treatment using an AI-integrated biosimulation platform K Chakravarty, VG Antontsev, M Khotimchenko, N Gupta, A Jagarapu, ... Molecules 26 (7), 1912, 2021 | 20 | 2021 |
| Scalable in silico simulation of transdermal drug permeability: Application of BIOiSIM platform N Maharao, V Antontsev, H Hou, J Walsh, J Varshney Drug design, development and therapy, 2307-2317, 2020 | 16 | 2020 |
| Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept NV Maharao, AA Joshi, PM Gerk Biopharmaceutics & Drug Disposition 38 (2), 139-154, 2017 | 10 | 2017 |
| Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability N Maharao, J Venitz, PM Gerk Biopharmaceutics & Drug Disposition 40 (1), 18-31, 2019 | 8 | 2019 |
| Simultaneous quantitation of buprenorphine and its metabolites using LC–MS NV Maharao, PM Gerk, AA Joshi MJH Life Sciences 14, 15–19-15–19, 2016 | 2 | 2016 |
| Predicting the Potential of Major Cannabinoids and Their Metabolites to Precipitate Cytochrome P450‐mediated Drug Interactions S Bansal, N Maharao, M Paine, J Unadkat The FASEB Journal 35, 2021 | 1 | 2021 |
| Development of an Accurate AI/ML-Driven COVID-19 Patient Stratification Model Predicting Disease Outcomes from Disproportionate and Scarce Clinical Datasets M Khotimchenko, Y Bundey, R Bhave, H Hou, J Walsh, S Baran, ... ML-Driven COVID-19 Patient Stratification Model Predicting Disease Outcomes …, 2023 | | 2023 |
| Use of GRAS or dietary compounds to improve the oral bioavailability of buprenorphine NV Maharao, PM Gerk Drug Metabolism and Pharmacokinetics 33 (1), S25, 2018 | | 2018 |
| Determining the potency of inhibition of five GRAS or dietary compounds to inhibit the oxidative and conjugative metabolism of buprenorphine NV Maharao, PM Gerk Drug Metabolism and Pharmacokinetics 33 (1), S53, 2018 | | 2018 |
| Inhibition of Oxidative and Conjugative Metabolism of Buprenorphine Using Generally Recognized As Safe (GRAS) Compounds or Components of Dietary Supplements NV Maharao Virginia Commonwealth University, 2017 | | 2017 |
